Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Anticancer Drug SyB L-0501 Starts PII Trial for Refractory, Relapsed Multiple Myeloma (MM): SymBio
November 16, 2011
- MEDINET Initiates Clinical Study of DC Vaccine
November 16, 2011
- Japan’s Jul-Sep 2011 Ethical Drug Market Grows 7.7%: IMS Japan
November 15, 2011
- Domestic Vaccine Market Showing Strong Growth
November 15, 2011
- Sawai President to Increase “Hospital MRs” to 100
November 15, 2011
- CMIC to Develop Orphan Drugs With Partners, Funds: Chairman Nakamura
November 15, 2011
- Bayer Yakuhin Modifies Storage Conditions for Kogenate FS for Home Use
November 15, 2011
- EPS: Solid Growth in Sales, Profits Driven by SMO, CSO Businesses
November 15, 2011
- Otsuka Draws Up Strategy in Anticipation of Abilify Patent Expiration
November 14, 2011
- Otsuka Forms Alliance with Lundbeck in CNS Field
November 14, 2011
- Astellas Completes Recombinant Flu Vaccine Inoculation of Subjects of PII Trials
November 14, 2011
- SymBio Initiates Domestic PII Clinical Trials of Bendamustine for Add’l Indications
November 14, 2011
- Pharmaceutical Sales Down 2.2 % due to Decrease in Sales of Elplat: Yakult
November 14, 2011
- Antibody Drugs to Support Kyowa Kirin’s Growth Over Next 10 Years: Dr Oshima
November 14, 2011
- Sawai’s Sales Up 4.3%, Showed Sluggish Growth Due to Break in Positive Impact of 2010 Premium Revision
November 14, 2011
- Rohto: Sales, Profits Driven By Growth in Asian Market
November 14, 2011
- Favorable Results from PII Trial of Ono’s Ca Receptor Agonist Announced in US
November 14, 2011
- Meiji HD: Pharmaceutical Sales Up 1% in Apr-Sep on Reflex Growth
November 11, 2011
- Top-3 GE Makers Report 10.4% Increase in Sales; Pace Down from Year Before
November 11, 2011
- Otsuka HD: Pharmaceutical Sales Up 1.7% in Apr-Sep Driven by Abilify
November 11, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…